The evolution of thalidomide and its IMiD derivatives as anticancer agents

Nat Rev Cancer. 2004 Apr;4(4):314-22. doi: 10.1038/nrc1323.
No abstract available

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / pharmacology
  • Angiogenesis Inhibitors / therapeutic use
  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Clinical Trials as Topic
  • Humans
  • Lenalidomide
  • Multiple Myeloma / drug therapy
  • Neoplasms / drug therapy*
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology
  • Thalidomide / analogs & derivatives*
  • Thalidomide / pharmacology
  • Thalidomide / therapeutic use*
  • Tumor Necrosis Factor-alpha / drug effects

Substances

  • Angiogenesis Inhibitors
  • Anti-Inflammatory Agents
  • Antineoplastic Agents
  • Tumor Necrosis Factor-alpha
  • Thalidomide
  • pomalidomide
  • Lenalidomide